SAFETY AND EFFICACY OF HYDROXYUREA AS A PROPHYLACTIC THERAPY FOR SICKLE CELL

羟基脲作为镰状细胞预防疗法的安全性和有效性

• 批准号: 7625492
• 负责人: Eugene P Orringer
• 金额: $ 0.08万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7625492
• 关键词: Clinical; Computer Retrieval of Information on Scientific Projects Database; Control Groups; Double-Blind Method; Erythrocytes; Fetal Hemoglobin; Funding; Grant; Institution; Patients; Placebos; Production; Purpose; Randomized; Research; Research Personnel; Resources; Safety; Sickle Cell; Sickle Cell Anemia; Source; United States National Institutes of Health; hydroxyurea; prophylactic

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this double-blind, randomized study is: a) to compare the clinical course of patients receiving hydroxyurea to a control group receiving placebo and; b) to quantitate the effect of hydroxyurea on fetal hemoglobin production in the red blood cells of patients with sickle cell anemia.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项双盲、随机研究的目的是：a）比较接受羟基脲治疗的患者与接受安慰剂治疗的对照组的临床病程; B）定量测定羟基脲对镰状细胞性贫血患者红细胞中胎儿血红蛋白生成的影响。